Tower Research Capital LLC TRC Invests $48,000 in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Tower Research Capital LLC TRC acquired a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 9,298 shares of the company’s stock, valued at approximately $48,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James & Associates acquired a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth $52,000. BML Capital Management LLC increased its holdings in shares of Vistagen Therapeutics by 50.0% during the 4th quarter. BML Capital Management LLC now owns 150,000 shares of the company’s stock worth $771,000 after buying an additional 50,000 shares during the last quarter. Blair William & Co. IL acquired a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth $446,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth $726,000. Finally, Armistice Capital LLC acquired a new stake in shares of Vistagen Therapeutics during the 4th quarter worth $2,457,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Vistagen Therapeutics Stock Up 1.3 %

Vistagen Therapeutics stock traded up $0.06 during trading on Tuesday, reaching $4.83. 474,142 shares of the company’s stock were exchanged, compared to its average volume of 278,917. The company’s 50-day moving average is $4.74 and its two-hundred day moving average is $4.46. Vistagen Therapeutics, Inc. has a 52-week low of $1.62 and a 52-week high of $24.71.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.09. Vistagen Therapeutics had a negative net margin of 3,073.51% and a negative return on equity of 72.10%. The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.73 million. Equities research analysts forecast that Vistagen Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.